Please select an option below to help us tailor your newsletter to best suit your content interests!
An open-label, multicenter, randomized Phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer
VIEW TRIAL ON CLINICALTRIALS.GOVColon, Rectum, Colorectal
Stage 4
Phase 3
Open to Enrollment
Encorafenib, cetuximab
BRAF inhibitor, EGFR antibody
Axel Grothey, MD
Pfizer
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)
VIEW TRIAL ON CLINICALTRIALS.GOVColon, Rectal, Colorectal
Stage 4
Phase 3
Open to Enrollment
Maintenance (after 1st Line)
Olaparib + Bevacizumab
PARP inhibitor
Axel Grothey, MD
Merck Sharp & Dohme Corp
Adenocarcinoma
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVUrothelial Neoplasm, Bladder Cancer, Renal Cell Carcinoma, Head and Neck, Lung Cancer, NSCLC, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Melanoma
Stage 4
Phase 1
Open to Enrollment
1st or later
DSP-7888
peptide vaccine stimulating cytotoxic T-cells expressing WT1
Dan Vaena, MD
Sumitomo Dainippon Pharma Oncology Inc.
Carcinoma
A Phase 1/2 first-in-human study of BMS-986258 alone and in combination with nivolumab in advanced malignant tumors
VIEW TRIAL ON CLINICALTRIALS.GOVRenal cell (kidney), CRC (colon, rectal, colorectal), lung cancer (NSCLC), Head and Neck (SCCHN), Triple Negative Breast (TNBC)
Stage 4
Phase 1
Open to Enrollment
2nd line or greater
BMS 986258
TIM-3 antibody
Dan Vaena, MD
Bristol Myers Squibb
Lung- non-small cell; Breast- Triple Negative; RCC- clear cell; CRC- any; SCCHN- any